MED
MED
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
1
$226K
Total Volume
$226K
1 transactions
Net Activity
$226K
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
MED has an insider buy conviction of 0%, compared to the Unknown sector buy average of 50%.
Chard Daniel R
Dir
$226K total
Over the last 90 days, corporate insiders at MED (MED) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 1 were sales. The total volume of insider trading reached $226K.
The net insider activity for MED shows a net selling bias of $226K. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Chard Daniel R (Dir), who traded 19.1K shares valued at $226K on Sep 28, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering MED and the Unknown sector.
How to Interpret Insider Trading Data: A Comprehensive Guide
A beginner-to-intermediate guide on reading SEC Form 4 filings: what each transaction code means, how to calculate purchase significance relative to net worth, and which context clues separate signal buys from noise.
Why Biotech Insiders Purchase Prior to Phase 3 Results
Buying stock before Phase 3 results is the highest-risk insider trade in biotech. This report examines the legal boundaries, the statistical frequency of such purchases, and whether insiders who buy pre-Phase-3 have historically outperformed those who buy after.
How the Stock Market Reacts to Sudden CEO Resignations and Insider Sells
When a CEO abruptly resigns with a cluster of insider sells immediately following, the market often misses the full picture. This event study tracks 90-day price reactions to sudden leadership changes paired with Form 4 selling activity.
Venture Capital Liquidity Windows: The Role of Direct Listings
Direct listings bypass traditional lock-up structures, giving all shareholders immediate liquidity. This report compares insider trading patterns at direct-listing companies versus traditional IPOs, examining whether the absence of lock-ups changes post-public executive behavior.
Tracking Executive Transitions: When New CEOs Buy Stock Immediately
A new CEO buying stock in the open market within their first 90 days is one of the clearest signals of genuine conviction. This report tracks Day-1 buyer CEOs, their transaction sizes, and 24-month price performance relative to sector peers.
The History of the SEC EDGAR System and Retail Financial Sourcing
SEC EDGAR launched in the early 1990s and transformed public access to corporate filings. This history traces how EDGAR evolved from a paper-replacement system into the real-time data source powering modern quantitative insider-trading research.
FAQs About MED Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for MED.